Cover Image

Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent skeletal muscle dystrophies. Skeletal muscle pathology in individuals with FSHD is caused by inappropriate expression of the transcription factor DUX4, which activates different myotoxic pathways. At the moment there is no mo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Linde F. Bouwman (Author), Bianca den Hamer (Author), Anita van den Heuvel (Author), Marnix Franken (Author), Michaela Jackson (Author), Chrissa A. Dwyer (Author), Stephen J. Tapscott (Author), Frank Rigo (Author), Silvère M. van der Maarel (Author), Jessica C. de Greef (Author)
Format:	Book
Published:	Elsevier, 2021-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy
by: Darina Šikrová, et al.
Published: (2021)

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
by: Virginie Mariot, et al.
Published: (2020)

RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
by: Virginie Mariot, et al.
Published: (2021)

p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy
by: Darko Bosnakovski, et al.
Published: (2017)

Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models
by: Andreia M. Nunes, et al.
Published: (2021)

Genetics of Facioscapulohumeral Dystrophy
by: J Gordon Millichap
Published: (1996)

Hearing Loss in Facioscapulohumeral Dystrophy
by: J Gordon Millichap
Published: (2008)

Genetics of Facioscapulohumeral Muscular Dystrophy
by: J Gordon Millichap
Published: (1991)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Silvana M G Jirka, et al.
Published: (2015)

Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy
by: Kenji Rowel Q. Lim, et al.
Published: (2021)

Coats Syndrome in Facioscapulohumeral Dystrophy Type 1
by: J Gordon Millichap
Published: (2013)

Cellular and animal models for facioscapulohumeral muscular dystrophy
by: Alec M. DeSimone, et al.
Published: (2020)

Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy
by: Ningyan Hu, et al.
Published: (2021)

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
by: Dominic Jauvin, et al.
Published: (2017)

Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model
by: Karima Relizani, et al.
Published: (2017)

Orofacial Muscle Weakening in Facioscapulohumeral Muscular Dystrophy (FSHD) Patients
by: Dimitrios Konstantonis, et al.
Published: (2022)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
by: Lodewijk J.A. Toonen, et al.
Published: (2017)

Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry
by: Jaeah Kim, et al.
Published: (2019)

Tissue pharmacokinetics of antisense oligonucleotides
by: Erica Bäckström, et al.
Published: (2024)

Pharmacokinetics of antisense oligonucleotide drugs
by: M. R. Khaitov, et al.
Published: (2013)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
by: Naoki Watanabe, et al.
Published: (2018)

Antisense Oligonucleotides: Concepts and Pharmaceutical Applications
by: Ariana Araya, et al.
Published: (2023)

Acupuncture Improves the Facial Muscular Function in a Case of Facioscapulohumeral Muscular Dystrophy
by: Yutan Liu, et al.
Published: (2019)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
by: Tomoko Nishina, et al.
Published: (2015)

Antisense Oligonucleotide-Based Therapy of Viral Infections
by: Woan-Yuh Tarn, et al.
Published: (2021)

Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy
by: Elena Marrosu, et al.
Published: (2017)

Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging
by: Mauro Monforte, et al.
Published: (2019)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
by: van Ommen Gert-Jan B, et al.
Published: (2007)

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
by: Jeroen Bremer, et al.
Published: (2016)

Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290
by: Rob WJ Collin, et al.
Published: (2012)

The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice
by: Ingrid E C Verhaart, et al.
Published: (2014)

Cognitive behavioural therapy for reducing fatigue in post-polio syndrome and in facioscapulohumeral dystrophy: A comparison
by: Fieke S. Koopman, et al.
Published: (2017)

The development of myasthenia gravis in a patient with facioscapulohumeral muscular dystrophy: case report and literature review
by: Feryal Nauman, et al.
Published: (2019)

Five‐year follow‐up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome
by: Sanne C.C. Vincenten, et al.
Published: (2023)

Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice
by: Karah Nazor Friberg, et al.
Published: (2012)

Antisense oligonucleotides: a novel Frontier in pharmacological strategy
by: D. Collotta, et al.
Published: (2023)

Antisense oligonucleotide is a promising intervention for liver diseases
by: Kailing Lu, et al.
Published: (2022)

New treatments for myasthenia: a focus on antisense oligonucleotides
by: Angelini C, et al.
Published: (2013)

Therapy with 2'-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption
by: Manoe J. Janssen, et al.
Published: (2019)